Literature DB >> 17182090

Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.

Nancy K Mello1, S Stevens Negus, Kenner C Rice, Jack H Mendelson.   

Abstract

Cocaine stimulates the rapid release of ACTH, and by inference, CRF in several species, suggesting that the HPA "stress" axis may contribute to the abuse-related effects of cocaine. The effects of a systemically-active CRF(1) receptor antagonist, antalarmin, on cocaine self-administration and cocaine discrimination were examined in rhesus monkeys. Antalarmin's acute (1-10 mg/kg, IV) and chronic (3.2 mg/kg IV) effects on IV cocaine self-administration were studied. The acute effects of 3.2 mg/kg IV antalarmin on the cocaine self-administration dose-effect curve (0.001-0.10 mg/kg/inj) were also examined. The acute effects of antalarmin (5 and 10 mg/kg, IM) on the cocaine discrimination dose-effect curve (0.013-1.3 mg/kg) were examined. Antalarmin did not significantly decrease the reinforcing or the discriminative stimulus effects of cocaine. Acute antalarmin administration produced a dose-dependent but non-significant decrease in self-administration of 0.01 mg/kg/inj cocaine but did not alter the cocaine dose-effect curve. Chronic daily antalarmin treatment did not significantly decrease cocaine-maintained responding. Antalarmin did not significantly alter either the cocaine discrimination dose-effect curve or the time course of the cocaine-training dose. Antalarmin (10 mg/kg) produced sedation, suggesting that it was centrally active, however, it did not attenuate cocaine's abuse-related effects in rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182090     DOI: 10.1016/j.pbb.2006.11.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

Review 2.  Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.

Authors:  Marian L Logrip; George F Koob; Eric P Zorrilla
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

4.  CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats.

Authors:  Sheila E Specio; Sunmee Wee; Laura E O'Dell; Benjamin Boutrel; Eric P Zorrilla; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2007-10-30       Impact factor: 4.530

Review 5.  A neuropeptide-centric view of psychostimulant addiction.

Authors:  B Boutrel
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

6.  Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.

Authors:  S S Negus; M H Baumann; R B Rothman; N K Mello; B E Blough
Journal:  J Pharmacol Exp Ther       Date:  2009-01-16       Impact factor: 4.030

7.  Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  S S Negus; N K Mello; H L Kimmel; L L Howell; F I Carroll
Journal:  Pharmacol Biochem Behav       Date:  2008-08-08       Impact factor: 3.533

Review 8.  Effect of early life social adversity on drug abuse vulnerability: Focus on corticotropin-releasing factor and oxytocin.

Authors:  Michael T Bardo; Lindsey R Hammerslag; Samantha G Malone
Journal:  Neuropharmacology       Date:  2021-04-13       Impact factor: 5.273

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.